Downloading...
Download

Biopharmaceuticals

Vericel (VCEL) AnalysisCompany Overview: Vericel is a biopharmaceutical company specializing in cellular treatments for severe burn care and sports medicine. The company's flagship product, MACI, is used for knee cartilage replacement and has been a significant growth driver, achieving a 22% revenue increase along with record numbers of implants, biopsies, and surgeon usage. Product Pipeline: Vericel is poised to launch two potential blockbuster drugs: Epicel: A skin graft for severe burns, which also experienced a 22% revenue growth. Nexobrid: An ointment for removing dead burned skin to improve healing, became available in Q4. Investment Outlook: Bullish Outlook: We are bullish on NASDAQ:VCEL above the $43.00-$44.00 range. Upside Potential: With an upside target set at $64.00-$65.00, investors should consider Vericel's strong product performance and promising pipeline as key drivers for potential stock appreciation. 📈🔍 Monitor Vericel for promising investment opportunities! #VCEL #Biopharmaceuticals 💉🏥
NASDAQ:VCELLong
by Richtv_official
Potential break through $3 scenario for CNTBAfter the good news this morning, the CNTB just got a big dip from one of the whales with weak resistance buyback force resulting in a sum of 3mil shares exchanged between buy and sale leading to a current ~$1.4. However, I noticed a similar pattern around October time where a bullish push for $1.2 and a big dip after that down to $0.79. This dip is almost 36% dip while we are experiencing $1.4 from $2.89 which is dip %51. This dip is much larger than the previous dip with potentially an uptrend bullish run for CNTB for the next 1 month run to above $3. This is a bullish scenario for the CNTB and hopefully, we will see the result of the fight between the bull and the bear! This is not financial advice but my update views on CNTB's position after recent good news!
NASDAQ:CNTBLong
by Hamahamieng
New long hold for good startup Biopharma companyWithout looking at the news, the CNTB should have gone down to get more air and stay around the $1.6 zone to be attractive. However, the new news regarding Simcere obtained the exclusive deal with CNTB regarding phase 3 drug rademikibart providing CNTB immediate big funding ($21M-$121M). This may signal a very bullish run if the market receives this news as excitement. The CNTB is still able to develop and commercialize rademikibart elsewhere aside from the greater China region (China, Hong Kong, Taiwan, Macau). We detect here a Cup and handle patterns and suspect there would be a breakthrough ceiling at $2.83 after rallying around $2.5. This is not financial advice but my view on CNTB at the current time!
NASDAQ:CNTBLong
by Haizsama
1
ENZC Elliot Wave ProjectionWave 1 is the start of a bullish trend, it is SUPER hard to catch, usually everyone is pessimistic on the stock and nobody believes the move that its making. Wave 2. where we currently are and possibly just finished.... usually has lower volume than wave 1, The price usually does NOT go below 0.618 fib retracement line (which we haven't) :), however sometimes but rarely it does.... The price usually falls in an ABC type of wave, which we currently saw last week. Phase 2 is where the shorts try to take over, the bears eat away at the ones scared to hold onto profits as we attempt to retest phase 1 lows. If you follow charts we ALWAYS retrace and test an old resistance like where we fail and drop harder, or buyers come in and we make the previous resistance a new support. wave 3 THE EXCITING WAVE!!!!!!!! Usually the most POWERFUL and largest wave in a trend. (some would argue wave 5 is, but not necessarily true... Wave 3 - the news is now POSITIVE and fundamental analysts start to raise earnings targets and estimates.... *prices rise quickly and corrections are short lived. Anyone looking to get in on a pullback will likely "miss the boat" Wave 3 OFTEN extends wave 1 by a target ratio of 1.618 aka the GOLDEN POCKET!
OTC:ENZCLong
by OptionStonker
2
Vistagen (VTGN): Long-term Game-changer* This is not financial advice. This is my non-expert opinion. * Vistagen ( NASDAQ:VTGN ) is a clinical stage biopharmaceutical company with long-term potential. I believe it's technology is similarly game-changing the way I believe NanoFlu for Novavax is (www.novavax.com) ( ). It could have positive outcomes for the world. I hope that their tech comes to fruition. Their pipeline includes Neuroactive nasal sprays that don't involve benzodiazepine and its associated side effects. I hope they succeed because it could change the way patients with anxiety or depression-related disorders are treated. Vistagen: www.vistagen.com Pipeline: www.vistagen.com PH94B Neuroactive Nasal Spray is their most advanced candidate, which is currently in Stage 3 clinical trials. I encourage anyone who wants to do their own research. This animated demonstration was very informative for me www.youtube.com Keep an eye out for this company.
NASDAQ:VTGNLong
by traderman001
Benitec Biopharma Inc. BNTC can explode anytime nowBenitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. (Source: Yahoo Finance) On April 15, 2020, the Company completed the re-domiciliation of the Company from Australia to the United States. As a result, the Company is now incorporated in the United States and its common stock is listed on Nasdaq. (Source: prnewswire.com) Market Cap 17.093M Please leave me a message if you want to test the buy and sell indicators that i am using.
NASDAQ:BNTCLong
by BuySellMarketMaker
2
Exclusive Licensing Agreement for GIAPREZA and XERAVA in EuropeLa Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe La Jolla to receive upfront cash payment of $22.5 million plus potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments Under the terms of the exclusive licensing agreement, La Jolla will be entitled to receive: (i) an upfront cash payment of $22.5 million; (ii) potential commercial milestone payments of up to $109.5 million; and (iii) double-digit tiered royalty payments based on net sales of GIAPREZA and XERAVA. In exchange, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the Territories. finance.yahoo.com
L
by AlenCiken
positive prelim data from a Phase 1 study-leukemia treatmentCuris Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes. Key findings include: - Marrow blast reductions observed in all evaluable patients (6 patients). - 6 of 7 patients enrolled remain on study. - Patients enrolled experienced a median of 3 prior lines of treatment (range 1-4). - Two patients experienced a marrow complete response, one with blast count going from 23% pretreatment to 1% on treatment, and the other going from 11% pretreatment to 2% on treatment. - No DLTs observed in 7 DLT-evaluable patients in the 200 mg BID and 300 mg BID cohorts. - Enrollment has begun in the 400 mg BID cohort. Curis said its CA-4948 monotherapy in adult patients was well tolerated, has demonstrated signs of biologic activity in the ongoing study and is capable of achieving "relevant levels of drug exposure." finance.yahoo.com
NASDAQ:CRIS
by AlenCiken
Big Rock Partners Acquisition Corp Announces Merger with NeuroRxBig Rock Partners Acquisition Corp. Announces Merger with NeuroRx, Inc. Combined Company to Have an Estimated Post-Transaction Equity Value in Excess Of $500 Million (Excluding Potential Earnout Payments), Assuming A Share Price Of At Least $10.00 Per Share NeuroRx, Inc. is a clinical stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of COVID-19 (RLF-100 or "ZYESAMI™ (aviptadil)") and Bipolar Depression (NRX-100, 101) The transaction is expected to occur in the first or second quarter of 2021. Under the terms of the transaction, Big Rock will issue to NeuroRx's current equity holders an aggregate of 50 million shares of Big Rock common stock for their interests in NeuroRx ubject to certain conditions, an aggregate of 25 million additional shares of Big Rock common stock will be issued to NeuroRx pre-merger equity holders if, prior to December 31, 2022, (1) RLF-100 receives emergency use authorization by the FDA and (2) the FDA accepts the Company's filing of its application to approve RLF-100. In addition, subject to certain conditions, a $100 million cash earnout may be payable to NeuroRx pre-merger equity holders if, prior to December 31, 2022, either (1) FDA approval of the Company's COVID-19 Drug is obtained and the Company's COVID-19 Drug is listed in the FDA's "Orange Book" or (2) FDA approval of the Company's Antidepressant Drug Regimen is obtained and the Company's Antidepressant Drug Regimen is listed in the FDA's "Orange Book". finance.yahoo.com
B
by AlenCiken
2
CYCC Announces at-the-market $7 Million Strategic InvestmentCyclacel Pharmaceuticals Announces at-the-market $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures Cyclacel Pharmaceuticals has entered into a definitive securities purchase agreement with Acorn Bioventures, LP, a biotech-focused fundamental investor. - Strategic investment from single biotech-focused institutional investor - - Enables clinical development of both fadraciclib and CYC140 in hematological malignancies and solid tumors - Acorn Bioventures has agreed to purchase in a registered direct offering 485,912 shares of common stock and 237,745 shares of newly designated Series B Preferred Stock (convertible into shares of common stock at a ratio of 1:5), and in a concurrent private placement, warrants to purchase 669,854 shares of common stock, for aggregate gross proceeds of approximately $7 million. The warrants will be exercisable beginning twelve months following the date of issuance, will expire on the five-year anniversary of the date of issuance, and have an exercise price of $4.13 per share. finance.yahoo.com
NASDAQ:CYCC
by AlenCiken
Solid Biosciences Announces $90 Million Private PlacementSolid Biosciences Announces $90 Million Private Placement Solid Biosciences has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $90 million private placement, which is expected to close on or about December 15, 2020, subject to the satisfaction of customary closing conditions. The private placement includes new investors Suvretta Capital Management, LLC and Aspire Capital Fund, LLC and existing investors, including RA Capital Management, Perceptive Advisors, LLC, Bain Capital Life Sciences, EcoR1 Capital, LLC, Boxer Capital, and Ikarian Capital, LLC, as well as certain board members and executive officers. In this private placement, the Company is selling 24,324,320 shares of common stock at a price of $3.70 per share. The Company expects to use net proceeds from the private placement to fund research and development expenses, including the advancement of SGT-001, and for working capital and other general corporate purposes. finance.yahoo.com
NASDAQ:SLDB
by AlenCiken
[NVAX] Novavax: Update - 1.6 billion funded!I still believe NVAX has a lot of potential and I'll say it again. My idea is clear that its NanoParticle and Matrix-M Adjuvant tech makes it a prime candidate for a COVID-19 vaccines. Even if it doesn't make it first (or ever), it still has major potential for the seasonal influenza (w/ NanoFlu) and its Respiratory Syncytial Virus (RSV) vaccine. Check out my original post that is linked. Today's News: 1. www.cnbc.com 2. www.fool.com
NASDAQ:NVAXLong
by traderman001